...
首页> 外文期刊>Cell Regulation >The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35
【24h】

The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35

机译:Munc 18(p67)与p35的p10结构域的相互作用可保护体内Cdk5 / p35活性免受TFP5(一种源自p35的肽)的抑制

获取原文
           

摘要

In a series of studies, we have identified TFP5, a truncated fragment of p35, the Cdk5 kinase regulatory protein, which inhibits Cdk5/p35 and the hyperactive Cdk5/p25 activities in test tube experiments. In cortical neurons, however, and in vivo in Alzheimer’s disease (AD) model mice, the peptide specifically inhibits the Cdk5/p25 complex and not the endogenous Cdk5/p35. To account for the selective inhibition of Cdk5/p25 activity, we propose that the “p10” N-terminal domain of p35, absent in p25, spares Cdk5/p35 because p10 binds to macromolecules (e.g., tubulin and actin) as a membrane-bound multimeric complex that favors p35 binding to Cdk5 and catalysis. To test this hypothesis, we focused on Munc 18, a key synapse-associated neuronal protein, one of many proteins copurifying with Cdk5/p35 in membrane-bound multimeric complexes. Here we show that, in vitro, the addition of p67 protects Cdk5/p35 and has no effect on Cdk5/p25 activity in the presence of TFP5. In cortical neurons transfected with p67siRNA, we also show that TFP5 inhibits Cdk5/p35 activity, whereas in the presence of p67 the activity is protected. It does so without affecting any other kinases of the Cdk family of cyclin kinases. This difference may be of significant therapeutic value because the accumulation of the deregulated, hyperactive Cdk5/p25 complex in human brains has been implicated in pathology of AD and other neurodegenerative disorders.
机译:在一系列研究中,我们确定了TFP5(p35的截短片段),Cdk5激酶调节蛋白,该蛋白在试管实验中抑制Cdk5 / p35和过度活跃的Cdk5 / p25活性。然而,在皮层神经元中和在阿尔茨海默氏病(AD)模型小鼠体内,该肽特异性抑制Cdk5 / p25复合物,而不抑制内源性Cdk5 / p35。为了说明对Cdk5 / p25活性的选择性抑制,我们提出p25中不存在的p35的“ p10” N末端结构域可保留Cdk5 / p35,因为p10结合大分子(例如微管蛋白和肌动蛋白)作为膜,结合的多聚体复合物,有利于p35与Cdk5结合和催化。为了验证该假设,我们集中研究了与突触相关的关键神经元蛋白Munc 18,这是膜结合多聚体复合物中与Cdk5 / p35共纯化的许多蛋白之一。在这里,我们表明,在体外,在TFP5存在下,p67的添加可保护Cdk5 / p35,并且对Cdk5 / p25活性没有影响。在用p67siRNA转染的皮质神经元中,我们还显示TFP5抑制Cdk5 / p35活性,而在存在p67的情况下,该活性受到保护。这样做不会影响细胞周期蛋白激酶Cdk家族的任何其他激酶。这种差异可能具有重要的治疗价值,因为在人脑中失活的,过度活跃的Cdk5 / p25复合物的积累与AD和其他神经退行性疾病的病理学有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号